Clinical Trials
27 trialsRegbone
Institute of Mother and Child, Warsaw, Poland
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
CheckMate 9N9
Bristol-Myers Squibb
ARC-9
Arcus Biosciences, Inc.
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Great Novel Therapeutics Biotech & Medicals Corporation
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
GOING
Fundacion Clinic per a la Recerca Biomédica
FaR-RMS
University of Birmingham
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
REGIRI
UNICANCER
REGOMUNE
Institut Bergonié
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
China Medical University, China
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Shanghai Changzheng Hospital
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
Sun Yat-sen University
REPEAT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
China Medical University, China